-
Electronic (PDF)
-
Site License
-
Enterprisewide
A Decision Support Tool for Optimizing The Lymphoma Pipeline: From Research and Development to Market
Bioseeker, May 2011, Pages: 954
This report comprises defined and up to date development strategies for 282 lymphoma drugs within the portfolio of 152 companies, from Ceased to Marketed. The report extensively analyses their 181 identified drug targets, organized into 173 drug target strategies, and assesses them in eight different compound strategies and five sub-indications of lymphoma. BioSeeker has applied its unique drug assessment methodology to stratify the lymphoma pipeline and discern the level of competition in fine detail.
Major Findings from this report:
- The identified competitive landscape of lymphoma drugs is split between the 49% which have unique drug target strategies and the other part which have head-to-head target competing lymphoma drugs in 36 different clusters. The latter has a competing ratio which is almost two and a half times higher than the comparable average of the lymphoma drugs in general. Contributing to this fact is heavily utilized drug target strategies like: MS4A1, TOP2A, ALK and CD19.
- Eight out of ten drug target strategies in Phase III development are new to lymphoma drugs and at the same time the greatest numbers of new target strategies are found in Phase I (33%) and Phase II development (27%).
- Small molecules, antibodies and proteins are the dominating compound strategies of lymphoma drugs, which represent 90% of the entire pipeline. Cell- and gene therapy based lymphoma drugs have the lowest representation in the defined target strategy portfolio compared to that of other compound strategies of lymphoma drugs.
- The highest number of described drug target strategies of lymphoma drugs belongs to Bristol-Myers Squibb (9), Hoffmann-La Roche (8), GlaxoSmithKline (8) and Pfizer (8).
The report is written for you to understand and assess the impact of competitor entry and corresponding changes to development strategies for your own portfolio products. It helps teams to maximize molecule value by selecting optimal development plans and manage risk and uncertainty.
The report serves as an external commercial advocate for pharmaceutical companies’ pipeline and portfolio planning (PPP) in cancer by:
- Providing you with competitive input to the R&D organization to guide development of early product ideas and ensure efforts are aligned with business objectives
- Assisting you to make informed decisions in selecting cancer indications that are known to be appropriate for your drug's properties
- Analyzing, correlating and integrating valuable data sources in order to provide accurate data for valuation of pipeline, in-licensing and new business opportunities
- Providing you with commercial analytic support for due diligence on in-licensing and acquisition opportunities
- Supporting development of integrative molecule, pathway and disease area strategies
- Integrating knowledge for you to consider the therapeutic target for the highest therapeutic outcome and return on investment
This report provides systems, analytical and strategic support both internally to PPP and to stakeholders across your own organization. The report will also be an important part of creating and implementing a market development plan for any lymphoma drug to ensure that the optimal market conditions exist by the time the product is commercialized.
1 Executive Summary
2 About Cancer Highlights™
2.1 Cancer Focus Areas
2.2 Subscribe Today and Start Saving
2.2.1 Type of License
2.3 Additional Information
2.4 BioSeeker Group’s Oncology Team
3 Methodology
3.1 Cancer Highlights Five Pillar Drug Assessment
4 Table of Contents
4.1 List of Figures
4.2 List of Tables
5 Introduction
5.1 The Scope of this Report
5.2 Definitions
5.3 Abbreviations
6 Consider the Therapeutic Target Among Lymphoma Drugs for the Highest Therapeutic Outcome and Return on Investment
6.1 Drug Repositioning in Oncology
6.2 Introduction to Targets of Lymphoma Drugs
6.2.1 Acid Phosphatase Activity Targets
6.2.2 Auxiliary Transport Protein Activity Targets
6.2.3 Carboxy-lyase Activity Targets
6.2.4 Caspase Activator Activity Targets
6.2.5 Catalytic Activity Targets
6.2.6 Cell Adhesion Molecule Activity Targets
6.2.7 Chaperone Activity Targets
6.2.8 Chemokine Activity Targets
6.2.9 Cysteine-type Peptidase Activity Targets
6.2.10 Cytokine Activity Targets
6.2.11 Deaminase Activity Targets
6.2.12 DNA Binding Targets
6.2.13 DNA Repair Protein Targets
6.2.14 DNA Topoisomerase Activity Targets
6.2.15 DNA-directed DNA Polymerase Activity Targets
6.2.16 DNA-methyltransferase Activity Targets
6.2.17 G-protein Coupled Receptor Activity Targets
6.2.18 Glutathione Transferase Activity Targets
6.2.19 Growth Factor Activity Targets
6.2.20 GTPase Activator Activity Targets
6.2.21 Hormone Activity Targets
6.2.22 Hydrolase Activity Targets
6.2.23 Kinase Activity Targets
6.2.24 Kinase Binding Targets
6.2.25 Kinase Regulator Activity Targets
6.2.26 Ligand-dependent Nuclear Receptor Activity Targets
6.2.27 Ligase Activity Targets
6.2.28 Lipid Kinase Activity Targets
6.2.29 Lipid Phosphatase Activity Targets
6.2.30 MHC Class I Receptor Activity Targets
6.2.31 Molecular Function Unknown Targets
6.2.32 Motor Activity Targets
6.2.33 Oxidoreductase Activity Targets
6.2.34 Phosphorylase Activity Targets
6.2.35 Protein Binding Targets
6.2.36 Protein Serine/Threonine Kinase Activity Targets
6.2.37 Protein Threonine/Tyrosine Kinase Activity Targets
6.2.38 Protein-tyrosine Kinase Activity Targets
6.2.39 Receptor Activity Targets
6.2.40 Receptor Binding Targets
6.2.41 Receptor Signaling Complex Scaffold Activity Targets
6.2.42 RNA Binding Targets
6.2.43 Serine-type Peptidase Activity Targets
6.2.44 Structural Constituent of Cytoskeleton Targets
6.2.45 Superoxide Dismutase Activity Targets
6.2.46 T Cell Receptor Activity Targets
6.2.47 Transcription Factor Activity Targets
6.2.48 Transcription Regulator Activity Targets
6.2.49 Translation Regulator Activity Targets
6.2.50 Transmembrane Receptor Activity Targets
6.2.51 Transmembrane Receptor Protein Tyrosine Kinase Activity Targets
6.2.52 Transporter Activity Targets
6.2.53 Ubiquitin-specific Protease Activity Targets
6.2.54 Other Targets
6.3 The Cancer Genome Project and Targets of Lymphoma Drugs
6.3.1 Targets of Lymphoma Drugs Present in the Cancer Gene Census and in the Catalogue of Somatic Mutations in Cancer
6.4 Structure-based Drug Design in Lymphoma Therapeutics is Stimulated by Available Structure Data on Biological Targets
6.5 Target-Target Interactions among Identified Targets of Lymphoma Drugs
6.6 The Drug-Target Competitive Landscape
6.7 Protein Expression Levels of Identified Targets of Lymphoma Drugs
6.8 Pathway Assessment of Lymphoma Drugs
6.8.1 Tools for Analysis of Cancer Pathways
6.8.2 Pathway Assessment
7 Emerging New Products to Established Ones: Drug Target Strategies of Lymphoma Drugs by their Highest Stage of Development
7.1 Pre-registration to Marketed: New and Unique Drug Target Strategies of Lymphoma Drugs
7.2 Phase III Clinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs
7.3 Phase II Clinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs
7.4 Phase I Clinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs
7.5 Preclinical Development: New and Unique Drug Target Strategies of Lymphoma Drugs
7.6 Drug Target Strategies of Suspended or Terminated Lymphoma Drugs
7.7 Target Strategy Development Profiles of Lymphoma Drugs
7.7.1 Marketed
7.7.2 Phase III
7.7.3 Phase II
7.7.4 Phase I
7.7.5 Preclinical
7.7.6 Suspended
7.7.7 Ceased
7.8 The Competition Through Close Mechanistic Approximation of Lymphoma Drugs
8 Compound Strategies at Work: Competitive Benchmarking of Lymphoma Drugs by Compound Strategy
8.1 Small Molecules
8.1.1 Background
8.1.2 Target Strategies of Small Molecule Drugs
8.2 Peptide & Protein Drugs
8.2.1 Background
8.2.2 Target Strategies of Peptide and Protein Drugs
8.3 Antibodies
8.3.1 Background
8.3.2 Target Strategies of Antibody Drugs
8.4 Nucleic Acid Therapies
8.4.1 Background
8.4.2 Target Strategies of Nucleic Acid Drugs
8.5 Cell & Gene Therapy
8.5.1 Background
8.5.2 Target Strategies of Cell and Gene Therapy Drugs
8.6 Drug Delivery and Nanotechnology
8.6.1 Background
8.6.2 Target Strategies of Reformulated Drugs
8.7 Compound Strategies based on Sub-Cellular Localization of Drug Targets
9 Selecting Subindication for Lymphoma Drugs
9.1 B-cell Lymphoma
9.2 Hodgkin's Lymphoma
9.3 non-Hodgkin's Lymphoma
9.4 T-cell Lymphoma
9.5 Lymphoma (general)
10 Pipeline and Portfolio Planning: Competitive Benchmarking of the Lymphoma Drug Pipeline by Investigator
10.1 Competitive Fall-Out Assessment
10.2 Changes in the Competitive Landscape: M&A, Bankruptcy and Name Change
10.3 4SC
10.4 Abbott
10.5 Abiogen
10.6 Advaxis
10.7 AEgera
10.8 AEterna Zentaris
10.9 Affimed Therapeutics
10.10 Agenus
10.11 Aida Pharmaceuticals
10.12 Alfa Wassermann
10.13 Alfacell
10.14 Allos Therapeutics
10.15 Ambit Biosciences
10.16 Amgen
10.17 Apricus Biosciences
10.18 Ariad
10.19 Arno Therapeutics
10.20 Ascenta Therapeutics
10.21 Astellas
10.22 Astex Therapeutics
10.23 AstraZeneca
10.24 Attenuon
10.25 AVEO
10.26 Bayer
10.27 Benitec
10.28 Biocon
10.29 BioCryst Pharmaceuticals
10.30 Biogen Idec
10.31 Biolex
10.32 Boehringer Ingelheim
10.33 Borean Pharma
10.34 Bristol-Myers Squibb
10.35 BTG
10.36 Celera
10.37 Celgene
10.38 Cell Therapeutics
10.39 Celldex Therapeutics
10.40 Celltrion
10.41 Cephalon
10.42 Cornerstone Pharmaceuticals 39
10.43 CureTech
10.44 Curis
10.45 Cyclacel
10.46 Cylene Pharmaceuticals
10.47 CytImmune Sciences
10.48 Cytokinetics
10.49 Daiichi Sankyo
10.50 Dainippon Sumitomo Pharma
10.51 Dara Biosciences
10.52 Dendreon
10.53 Dr Reddy's
10.54 Dynavax Technologies
10.55 Eisai
10.56 Eleos
10.57 Eli Lilly
10.58 Emergent BioSolutions
10.59 Enzon
10.60 EpiCept
10.61 Epizyme
10.62 Exelixis
10.63 Favrille
10.64 Forma Therapeutics
10.65 Gemin X Biotechnologies
10.66 Genencor
10.67 Genentech
10.68 Genmab
10.69 GenPat
10.70 Genta
10.71 Genzyme
10.72 Gilead Sciences
10.73 GlaxoSmithKline
10.74 Hayashibara
10.75 Heber Biotec
10.76 HemaQuest
10.77 Hoffmann-La Roche
10.78 Human Genome Sciences
10.79 Hy BioPharma
10.80 IGF Oncology
10.81 ImmunoGen
10.82 Immunomedics
10.83 Inex
10.84 Innate Pharma
10.85 InNexus Biotechnology
10.86 Inovio
10.87 Intas Biopharmaceuticals
10.88 Intracel
10.89 Italfarmaco
10.90 Johnson & Johnson
10.91 Kinex
10.92 Kissei
10.93 Kyowa Hakko Kirin
10.94 Leo
10.95 LG Life Sciences
10.96 Ligand
10.97 Lorus Therapeutics
10.98 MacroGenics
10.99 Meda
10.100 MedImmune
10.101 Merck & Co
10.102 Merck KGaA
10.103 MethylGene
10.104 Micromet
10.105 Nektar Therapeutics
10.106 Nereus Pharmaceuticals
10.107 Nerviano Medical Sciences
10.108 NIH – The US National Institute of Health
10.109 Non-industrial Sources
10.110 Novartis
10.111 Noxxon
10.112 Nycomed Pharma
10.113 Onconova
10.114 Oncothyreon
10.115 Otsuka
10.116 Pfizer
10.117 Pharmacyclics
10.118 PharmaMar
10.119 Philogen
10.120 Piramal
10.121 Plexxikon
10.122 Portola Pharmaceuticals
10.123 ProNAi Therapeutics
10.124 Reata Pharmaceuticals
10.125 Regeneron
10.126 Reliance Life Sciences
10.127 Rigel
10.128 Sanofi-Aventis
10.129 Santaris Pharma
10.130 SBIO
10.131 Seattle Genetics
10.132 Selvita
10.133 Semafore Pharmaceuticals
10.134 Shire
10.135 SuperGen
10.136 SuppreMol
10.137 Synageva BioPharma
10.138 Takeda
10.139 Tapestry Pharmaceuticals
10.140 Tekmira Pharmaceuticals
10.141 Telik
10.142 TetraLogic Pharmaceuticals
10.143 Teva
10.144 Titan Pharmaceuticals
10.145 TopoTarget
10.146 Transgene
10.147 Trion Pharma
10.148 Vaccinex
10.149 VentiRx Pharmaceuticals
10.150 Vertex Pharmaceuticals
10.151 Vion Pharmaceuticals
10.152 XBiotech
10.153 Xencor
10.154 Yakult Honsha
10.155 Zenotech
10.156 Zenyaku Kogyo
11 Disclaimer
12 Drug Index
13 Company Index
4.1 List of Figures
Figure 1: Visualization of Target-Target Interactions among Targets of Lymphoma Drugs
Figure 2: The Drug-Target Competitive Landscape of Lymphoma Drugs - Large Clusters
Figure 3: The Drug-Target Competitive Landscape Lymphoma Drugs - Smaller Clusters
Figure 4: Head-to-Head Targeting Competitive Landscape of Lymphoma Drugs
Figure 5: Distribution of Compound Strategies among Lymphoma Drugs
Figure 6: Primary Sub-cellular Localization of Drug Targets
4.2 List of Tables
Table 1: Cancer Highlights’™ Five Pillar Drug Assessment
Table 2: Breakdown of the Included Lymphoma Drug Pipeline by Stage of Development
Table 3: Head to Head Target Competition among Lymphoma Drugs
Table 4: Overview of Drug Target Strategy Themes
Table 5: Terminally Ceased Targets of Lymphoma Drugs
Table 6: Official Gene Name to Target Profle
Table 7: Targets of Lymphoma Drugs Present in the Catalogue of Somatic Mutations in Cancer and in the Cancer Gene Census
Table 8: Identity of Lymphoma Drug Targets with Available Biological Structures
Table 9: Number of Target-Target Interactions among Targets of Lymphoma Drugs
Table 10: Available Protein Expression Profiles of Lymphoma Drugs Targets
Table 11: Pathway Summary
Table 12: Drug Targets without any Identified Assigned Pathways
Table 13: Pathway Profiles According to BioCarta of Lymphoma Drug Targets
Table 14: Pathway Profiles According to KEGG of Lymphoma Drug Targets
Table 15: Pathway Profiles According to NetPath of Lymphoma Drug Targets
Table 16: Number of Drug Target Strategies by their Highest Developmental Stage and Uniqueness
Table 17: Top Competitive Target Strategies of Lymphoma Drugs
Table 18: New and Unique Target Strategies of Pre-registration and Marketed Lymphoma Drugs
Table 19: The Competition Through Close Mechanistic Approximation Between Lymphoma Drugs being Marketed or in Pre-registration
Table 20: New and Unique Target Strategies in Phase III Clinical Development of Lymphoma Drugs
Table 21: The Competition Through Close Mechanistic Approximation Between Phase III Lymphoma Drugs
Table 22: New and Unique Target Strategies in Phase II Clinical Development of Lymphoma Drugs
Table 23: The Competition Through Close Mechanistic Approximation Between Phase II Lymphoma Drugs
Table 24: New and Unique Target Strategies in Phase I Clinical Development of Lymphoma Drugs
Table 25: The Competition Through Close Mechanistic Approximation Between Phase I Lymphoma Drugs
Table 26: New and Unique Target Strategies in Preclinical Development of Lymphoma Drugs
Table 27: The Competition Through Close Mechanistic Approximation Between Preclinical Lymphoma Drugs
Table 28: Target Strategies of Suspended and Terminated Lymphoma Drugs
Table 29: Connecting Target Strategy with Its Profile Identification Number
Table 30: The Competition Through Close Mechanistic Approximation Among Lymphoma Drugs
Table 31: Overview of Compound Strategy Competition Among Lymphoma Drugs
Table 32: Overview of the Competitive Landscape of Small Molecule Based Lymphoma Drugs
Table 33: Competitive Comparison of Target Strategies of Small Molecule Lymphoma Drugs
Table 34: Pursued Target Strategies of Small Molecule Drugs Based Lymphoma Drugs
Table 35: Overview of the Competitive Landscape of Peptide Based Lymphoma Drugs
Table 36: Pursued Target Strategies of Peptide Based Lymphoma Drugs
Table 37: Overview of the Competitive Landscape of Protein Based Lymphoma Drugs
Table 38: Competitive Comparison of Target Strategies of Protein Based Lymphoma Drugs
Table 39: Pursued Target Strategies of Protein Based Lymphoma Drugs
Table 40: Overview of the Competitive Landscape of Antibody Based Lymphoma Drugs 616
Table 41: Competitive Comparison of Target Strategies of Antibody Based Lymphoma Drugs
Table 42: Pursued Target Strategies of Antibody Based Lymphoma Drugs
Table 43: Overview of the Competitive Landscape of Nucleic Acid Based Lymphoma Drugs
Table 44: Competitive Comparison of Target Strategies of Nucleic Acid Based Lymphoma Drugs
Table 45: Pursued Target Strategies of Nucleic Acid Based Lymphoma Drugs
Table 46: Potential Forms of Cell Therapy
Table 47: Vectors in Gene Therapy
Table 48: Overview of the Competitive Landscape of Cell Therapy Based Lymphoma Drugs
Table 49: Pursued Target Strategies of Cell Therapy Based Lymphoma Drugs
Table 50: Overview of the Competitive Landscape of Gene Therapy Based Lymphoma Drugs
Table 51: Pursued Target Strategies of Gene Therapy Based Lymphoma Drugs
Table 52:Overview of the Competitive Landscape of Reformulated Lymphoma Drugs
Table 53: Competitive Comparison of Target Strategies of Reformulated Lymphoma Drugs
Table 54: Pursued Target Strategies of Reformulated Lymphoma Drugs
Table 55: Compound Strategies based on Sub-Cellular Localization of Lymphoma Drug Targets
Table 56 Competitive Summary by Subindication of Lymphoma Drugs
Table 57: Target Strategy Development Profiles of Drugs for the Treatment of B-cell Lymphoma Drugs
Table 58: The Competition through Close Mechanistic Approximation between B-cell Lymphoma Drugs
Table 59: Target Strategy Development Profiles of Drugs for the Treatment of Hodgkin's Lymphoma
Table 60: The Competition through Close Mechanistic Approximation between Hodgkin's Lymphoma Drugs
Table 61: Target Strategy Development Profiles of Drugs for the Treatment of non-Hodgkin's Lymphoma
Table 62: The Competition through Close Mechanistic Approximation between non-Hodgkin's Lymphoma Drugs
Table 63: Target Strategy Development Profiles of Drugs for the Treatment of T-cell Lymphoma
Table 64: The Competition through Close Mechanistic Approximation between T-cell Lymphoma Drugs
Table 65: Target Strategy Development Profiles of Drugs for the Treatment of Lymphoma (general)
Table 66: The Competition through Close Mechanistic Approximation between Lymphoma (general) Drugs
Table 67: Example of a Competitive Fall-Out Table (Targeting MS4A1)
Table 68: Summary Table of Corporate Changes in the Competitive Landscape of Lymphoma Drug Development
Table 69: 4SC's Included Lymphoma Pipeline and Competitive Fall-Out
Table 70: Abbott's Included Lymphoma Pipeline and Competitive Fall-Out
Table 71: Abiogen's Included Lymphoma Pipeline and Competitive Fall-Out
Table 72: Advaxis’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 73: AEgera's Included Lymphoma Pipeline and Competitive Fall-Out
Table 74: AEterna Zentaris’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 75: Affimed Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 76: Agenus’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 77: Aida Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 78: Alfa Wassermann's Included Lymphoma Pipeline and Competitive Fall-Out
Table 79: Alfacell's Included Lymphoma Pipeline and Competitive Fall-Out
Table 80: Allos Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 81: Ambit Biosciences’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 82: Amgen's Included Lymphoma Pipeline and Competitive Fall-Out
Table 83: Apricus Biosciences’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 84: Ariad's Included Lymphoma Pipeline and Competitive Fall-Out
Table 85: Arno Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 86: Ascenta Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 87: Astellas’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 88: Astex Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 89: AstraZeneca's Included Lymphoma Pipeline and Competitive Fall-Out
Table 90: Attenuon's Included Lymphoma Pipeline and Competitive Fall-Out
Table 91: AVEO's Included Lymphoma Pipeline and Competitive Fall-Out
Table 92: Bayer's Included Lymphoma Pipeline and Competitive Fall-Out
Table 93: Benitec's Included Lymphoma Pipeline and Competitive Fall-Out
Table 94: Biocon's Included Lymphoma Pipeline and Competitive Fall-Out
Table 95: BioCryst Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 96: Biogen Idec's Included Lymphoma Pipeline and Competitive Fall-Out
Table 97: Biolex's Included Lymphoma Pipeline and Competitive Fall-Out
Table 98: Boehringer Ingelheim's Included Lymphoma Pipeline and Competitive Fall-Out
Table 99: Borean Pharma's Included Lymphoma Pipeline and Competitive Fall-Out
Table 100: Bristol-Myers Squibb's Included Lymphoma Pipeline and Competitive Fall-Out
Table 101: BTG's Included Lymphoma Pipeline and Competitive Fall-Out
Table 102: Celera's Included Lymphoma Pipeline and Competitive Fall-Out
Table 103: Celgene's Included Lymphoma Pipeline and Competitive Fall-Out
Table 104: Cell Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 105: Celldex Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 106: Celltrion's Included Lymphoma Pipeline and Competitive Fall-Out
Table 107: Cephalon's Included Lymphoma Pipeline and Competitive Fall-Out
Table 108: Cornerstone Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 109: CureTech's Included Lymphoma Pipeline and Competitive Fall-Out
Table 110: Curis’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 111: Cyclacel's Included Lymphoma Pipeline and Competitive Fall-Out
Table 112: Cylene Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 113: CytImmune Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 114: Cytokinetics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 115: Daiichi Sankyo's Included Lymphoma Pipeline and Competitive Fall-Out
Table 116: Dainippon Sumitomo Pharma's Included Lymphoma Pipeline and Competitive Fall-Out
Table 117: Dara Biosciences’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 118: Dendreon's Included Lymphoma Pipeline and Competitive Fall-Out
Table 119: Dr Reddy's’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 120: Dynavax Technologies’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 121: Eisai's Included Lymphoma Pipeline and Competitive Fall-Out
Table 122: Eleos’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 123: Eli Lilly's Included Lymphoma Pipeline and Competitive Fall-Out
Table 124: Emergent BioSolutions’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 125: Enzon's Included Lymphoma Pipeline and Competitive Fall-Out
Table 126: EpiCept's Included Lymphoma Pipeline and Competitive Fall-Out
Table 127: Epizyme's Included Lymphoma Pipeline and Competitive Fall-Out
Table 128: Exelixis’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 129: Favrille's Included Lymphoma Pipeline and Competitive Fall-Out
Table 130: Forma Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 131: Gemin X Biotechnologies’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 132: Genencor's Included Lymphoma Pipeline and Competitive Fall-Out
Table 133: Genentech's Included Lymphoma Pipeline and Competitive Fall-Out
Table 134: Genmab's Included Lymphoma Pipeline and Competitive Fall-Out
Table 135: GenPat77's Included Lymphoma Pipeline and Competitive Fall-Out
Table 136: Genta's Included Lymphoma Pipeline and Competitive Fall-Out
Table 137: Genzyme's Included Lymphoma Pipeline and Competitive Fall-Out
Table 138: Gilead Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 139: GlaxoSmithKline's Included Lymphoma Pipeline and Competitive Fall-Out
Table 140: Hayashibara's Included Lymphoma Pipeline and Competitive Fall-Out
Table 141: Heber Biotec's Included Lymphoma Pipeline and Competitive Fall-Out
Table 142: HemaQuest's Included Lymphoma Pipeline and Competitive Fall-Out
Table 143: Hoffmann-La Roche's Included Lymphoma Pipeline and Competitive Fall-Out
Table 144: Human Genome Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 145: Hy BioPharma's Included Lymphoma Pipeline and Competitive Fall-Out
Table 146: IGF Oncology's Included Lymphoma Pipeline and Competitive Fall-Out
Table 147: ImmunoGen's Included Lymphoma Pipeline and Competitive Fall-Out
Table 148: Immunomedics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 149: Inex's Included Lymphoma Pipeline and Competitive Fall-Out
Table 150: Innate Pharma's Included Lymphoma Pipeline and Competitive Fall-Out
Table 151: InNexus Biotechnology's Included Lymphoma Pipeline and Competitive Fall-Out
Table 152: Inovio's Included Lymphoma Pipeline and Competitive Fall-Out
Table 153: Intas Biopharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 154: Intracel's Included Lymphoma Pipeline and Competitive Fall-Out
Table 155: Italfarmaco's Included Lymphoma Pipeline and Competitive Fall-Out
Table 156: Johnson & Johnson's Included Lymphoma Pipeline and Competitive Fall-Out
Table 157: Kinex's Included Lymphoma Pipeline and Competitive Fall-Out
Table 158: Kissei's Included Lymphoma Pipeline and Competitive Fall-Out
Table 159: Kyowa Hakko Kirin's Included Lymphoma Pipeline and Competitive Fall-Out
Table 160: Leo's Included Lymphoma Pipeline and Competitive Fall-Out
Table 161: LG Life Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 162: Ligand's Included Lymphoma Pipeline and Competitive Fall-Out
Table 163: Lorus Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 164: MacroGenics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 165: Meda's Included Lymphoma Pipeline and Competitive Fall-Out
Table 166: MedImmune's Included Lymphoma Pipeline and Competitive Fall-Out
Table 167: Merck & Co's Included Lymphoma Pipeline and Competitive Fall-Out
Table 168: Merck KGaA's Included Lymphoma Pipeline and Competitive Fall-Out
Table 169: MethylGene's Included Lymphoma Pipeline and Competitive Fall-Out
Table 170: Micromet's Included Lymphoma Pipeline and Competitive Fall-Out 50
Table 171: Nektar Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 172: Nereus Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 173: Nerviano Medical Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 174: NIH's Included Lymphoma Pipeline and Competitive Fall-Out
Table 175: Non-industrial Source's Included Lymphoma Pipeline and Competitive Fall-Out
Table 176: Novartis’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 177: Noxxon's Included Lymphoma Pipeline and Competitive Fall-Out
Table 178: Nycomed Pharma's Included Lymphoma Pipeline and Competitive Fall-Out
Table 179: Onconova's Included Lymphoma Pipeline and Competitive Fall-Out
Table 180: Oncothyreon's Included Lymphoma Pipeline and Competitive Fall-Out
Table 181: Otsuka's Included Lymphoma Pipeline and Competitive Fall-Out
Table 182: Pfizer's Included Lymphoma Pipeline and Competitive Fall-Out
Table 183: Pharmacyclics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 184: PharmaMar's Included Lymphoma Pipeline and Competitive Fall-Out
Table 185: Philogen's Included Lymphoma Pipeline and Competitive Fall-Out
Table 186: Piramal's Included Lymphoma Pipeline and Competitive Fall-Out
Table 187: Plexxikon's Included Lymphoma Pipeline and Competitive Fall-Out
Table 188: Portola Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 189: ProNAi Therapeutics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 190: Reata Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 191: Regeneron's Included Lymphoma Pipeline and Competitive Fall-Out
Table 192: Reliance Life Sciences’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 193: Rigel's Included Lymphoma Pipeline and Competitive Fall-Out
Table 194: Sanofi-Aventis’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 195: Santaris Pharma's Included Lymphoma Pipeline and Competitive Fall-Out
Table 196: SBIO's Included Lymphoma Pipeline and Competitive Fall-Out
Table 197: Seattle Genetics’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 198: Selvita's Included Lymphoma Pipeline and Competitive Fall-Out
Table 199: Semafore Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 200: Shire's Included Lymphoma Pipeline and Competitive Fall-Out
Table 201: SuperGen's Included Lymphoma Pipeline and Competitive Fall-Out
Table 202: SuppreMol's Included Lymphoma Pipeline and Competitive Fall-Out
Table 203: Synageva BioPharma's Included Lymphoma Pipeline and Competitive Fall-Out
Table 204: Takeda's Included Lymphoma Pipeline and Competitive Fall-Out
Table 205: Tapestry Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 206: Tekmira Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 207: Telik's Included Lymphoma Pipeline and Competitive Fall-Out
Table 208: TetraLogic Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 209: Teva's Included Lymphoma Pipeline and Competitive Fall-Out
Table 210: Titan Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 211: TopoTarget's Included Lymphoma Pipeline and Competitive Fall-Out
Table 212: Transgene's Included Lymphoma Pipeline and Competitive Fall-Out
Table 213: Trion Pharma's Included Lymphoma Pipeline and Competitive Fall-Out
Table 214: Vaccinex's Included Lymphoma Pipeline and Competitive Fall-Out
Table 215: VentiRx Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 216: Vertex Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 217: Vion Pharmaceuticals’ Included Lymphoma Pipeline and Competitive Fall-Out
Table 218: XBiotech's Included Lymphoma Pipeline and Competitive Fall-Out
Table 219: Xencor's Included Lymphoma Pipeline and Competitive Fall-Out
Table 220: Yakult Honsha's Included Lymphoma Pipeline and Competitive Fall-Out
Table 221: Zenotech's Included Lymphoma Pipeline and Competitive Fall-Out
Table 222: Zenyaku Kogyo's Included Lymphoma Pipeline and Competitive Fall-Out
- 4SC
- Abbott
- Abiogen
- Advaxis
- AEgera
- AEterna Zentaris
- Affimed Therapeutics
- Agenus
- Aida Pharmaceuticals
- Alfa Wassermann
- Alfacell
- Allos Therapeutics
- Ambit Biosciences
- Amgen
- Apricus Biosciences
- Ariad
- Arno Therapeutics
- Ascenta Therapeutics
- Astellas
- Astex Therapeutics
- AstraZeneca
- Attenuon
- AVEO
- Bayer
- Benitec
- Biocon
- BioCryst Pharmaceuticals
- Biogen Idec
- Biolex
- Boehringer Ingelheim
- Borean Pharma
- Bristol-Myers Squibb
- BTG
- Celera
- Celgene
- Cell Therapeutics
- Celldex Therapeutics
- Celltrion
- Cephalon
- Cornerstone Pharmaceuticals
- CureTech
- Curis
- Cyclacel
- Cylene Pharmaceuticals
- CytImmune Sciences
- Cytokinetics
- Daiichi Sankyo
- Dainippon Sumitomo Pharma
- Dara Biosciences
- Dendreon
- Dr Reddy's
- Dynavax Technologies
- Eisai
- Eleos
- Eli Lilly
- Emergent BioSolutions
- Enzon
- EpiCept
- Epizyme
- Exelixis
- Favrille
- Forma Therapeutics
- Gemin X Biotechnologies
- Genencor
- Genentech
- Genmab
- GenPat
- Genta
- Genzyme
- Gilead Sciences
- GlaxoSmithKline
- Hayashibara
- Heber Biotec
- HemaQuest
- Hoffmann-La Roche
- Human Genome Sciences
- Hy BioPharma
- IGF Oncology
- ImmunoGen
- Immunomedics
- Inex
- Innate Pharma
- InNexus Biotechnology
- Inovio
- Intas Biopharmaceuticals
- Intracel
- Italfarmaco
- Johnson & Johnson
- Kinex
- Kissei
- Kyowa Hakko Kirin
- Leo
- LG Life Sciences
- Ligand
- Lorus Therapeutics
- MacroGenics
- Meda
- MedImmune
- Merck & Co
- Merck KGaA
- MethylGene
- Micromet
- Nektar Therapeutics
- Nereus Pharmaceuticals
- Nerviano Medical Sciences
- NIH – The US National Institute of Health
- Non-industrial Sources
- Novartis
- Noxxon
- Nycomed Pharma
- Onconova
- Oncothyreon
- Otsuka
- Pfizer
- Pharmacyclics
- PharmaMar
- Philogen
- Piramal
- Plexxikon
- Portola Pharmaceuticals
- ProNAi Therapeutics
- Reata Pharmaceuticals
- Regeneron
- Reliance Life Sciences
- Rigel
- Sanofi-Aventis
- Santaris Pharma
- SBIO
- Seattle Genetics
- Selvita
- Semafore Pharmaceuticals
- Shire
- SuperGen
- SuppreMol
- Synageva BioPharma
- Takeda
- Tapestry Pharmaceuticals
- Tekmira Pharmaceuticals
- Telik
- TetraLogic Pharmaceuticals
- Teva
- Titan Pharmaceuticals
- TopoTarget
- Transgene
- Trion Pharma
- Vaccinex
- VentiRx Pharmaceuticals
- Vertex Pharmaceuticals
- Vion Pharmaceuticals
- XBiotech
- Xencor
- Yakult Honsha
- Zenotech
- Zenyaku Kogyo
Also available
Customers who bought this item also bought
All rights reserved. © Copyright 2013 Research and Markets WWW5
Terms and Conditions Privacy Policy Publishers Employment Opportunities Site Map Link to us Webmaster Affiliate Network
